Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors

Introduction

Pancreatic neuroendocrine tumor (PanNET) is a heterogeneous group of neoplasms expressing hormones and general markers of neuroendocrine differentiation (Table 1) (1). Once considered rare tumors, the incidence of PanNETs has increased significantly over the last decades. Data from the US SEER database have shown that the number of new diagnoses per year rose almost 3-fold from 2000 to 2012, reaching 0.8 cases per 100,000 individuals (2). The increase of diagnoses has mostly concerned asymptomatic patients with localized low-/intermediate-grade tumors, due to the widespread use of cross-sectional imaging modalities. As a consequence, the number of pancreatic resections for PanNET has risen; consequently, PanNET is the second most frequent indication for pancreatic surgery following pancreatic adenocarcinoma (3). In 2019, the World Health Organization (WHO) has reclassified pancreatic neuroendocrine neoplasms (PanNEN) to distinguish well-differentiated neuroendocrine tumors (PanNETs), including high-grade, from poorly differentiated carcinomas (PanNECs) (1). PanNECs are characterized by a different pathological cellular morphology, higher proliferative index, and molecular alterations that correspond to a dismal prognosis therefore clearly categorizing them from well-differentiated PanNETs (1, 4, 5). While surgical resection represents the first-line treatment for localized PanNETs and is curative in 70–90% of cases, it is not indicated for PanNECs due to their poor prognosis, with systemic chemotherapy generally preferred (4, 6–8). For patients with a PanNET undergoing surgical resection, the risk of recurrence is widely heterogeneous and can persist for up to 10 years. Conventional staging and grading systems have been used to risk stratify patients; however, these approaches consider only a limited number of variables and include patients with variable tumor biology and subsequently risk of recurrence can be misclassified (9–11). Over recent years, to improve prognostication and establish more personalized surveillance schedules, several nomograms and predictive risk models incorporating multiple variables have been developed.

TABLE 1

Table 1. Pancreatic neuroendocrine neoplasm classification according to functional status and WHO classification (1).

At the same time, the genomic landscape of PanNETs has been comprehensively characterized, reaffirming molecular alterations in telomere maintenance and the mTOR pathway as indicators of aggressive tumor behavior. In particular, functional silencing of DAXX or ATRX genes promote the activation of the alternative lengthening of telomere (ALT) pathway and are commonly associated with the development of distant metastases, while the clinical significance of other molecular alterations is currently debated.

To date, consensus is lacking on which patients should be enrolled in postoperative surveillance programs, on the frequency and the length of the follow-up period, and on the optimal imaging modalities to employ (10–13). Without accurate stratification of the risk of recurrence, many patients will potentially be exposed to unnecessary imaging studies over a protracted period.

The purpose of this review article is to summarize the current evidence on the predictive clinicopathological and risk factors for PanNET recurrence, including an overview of the clinical available predictive models to manage surveillance following surgery. Herein, we will discuss the existing molecular data and determine strategies to integrate these data into the current clinical practice to better predict recurrence.

Recurrence After Curative Surgery

PanNET recurrence following curative surgery occurs in 8–17% of patients (9, 14, 15), significantly worsening the prognosis (14, 16). Data on patterns of recurrence are few and heterogeneous, due to several factors including the misclassification of high-grade PanNETs with PanNECs, the inconsistent inclusion of patients with a familial syndrome, and the heterogeneity of imaging protocols for diagnosis and follow-up of PanNET patients across countries and institutions.

Among patients undergoing surgery, commonly reported sites of recurrence are the liver, pancreas remnant, and lymph nodes (14, 17). Less frequently, other sites including lungs, bone, kidney, and peritoneum are involved (Figure 1). Liver involvement is the most frequent accounting for 50–83% of cases of recurrence. Data on the rate of pancreatic local recurrence and lymph nodes remains heterogeneous, ranging widely among surgical series, from 12–23% to 1–16%, respectively (14, 16, 17). While liver recurrence is associated with biological characteristics of the tumor and more specifically with a more aggressive phenotype, pancreatic local recurrence seems to be related to the presence of microscopical residual disease left on the surgical margins and therefore related to surgical procedure (14, 16). The discrepant rates of lymph nodal recurrence could be explained by the different imaging strategies employed during follow-up. The use of 68Ga-DOTATATE PET/CT has been approved in the USA by the Food and Drug Administration only in 2016, whereas its use for PanNET management had already been consolidated in Europe for several years. This imaging modality provides improved accuracy in identifying the presence of neuroendocrine disease compared to conventional imaging including Octreoscan and might have contributed to the higher rate of lymph-node recurrence reported in the European surgical series (18).

FIGURE 1

Figure 1. PanNET pattern of recurrence following surgical resection (14, 17).

An important question concerns whether the risk of recurrence is decreasing over time. Retrospective studies (9, 14) report a median time to recurrence of 35–37 months from surgery, but several cases recurred up to 10 years, advocating long follow-up (9, 14). Within the first 5 years after surgery, recurrence occurs at any site and might involve the liver, the remnant pancreas, lymph nodes, and other sites as lungs and bone, whereas late recurrences seem to affect mainly the liver (14, 17). However, prospective studies based on homogeneous and accurate preoperative diagnostic workup, to avoid stage underestimation at diagnosis, are needed to clarify those findings.

Clinical and Pathological Risk Factors for Recurrence

Functioning Status

PanNETs are classified into functioning (F-PanNET) and non-functioning (NF-PanNET) neoplasms according to the presence or the absence of a clinical hormone hypersecretion syndrome. The most common functioning PanNETs are insulinomas, gastrinomas, glucagonomas, and VIPomas. While previously it was suspected that the majority of resected PanNETs were functioning, with insulinomas being the most frequent type, recent data show that between 60 and 90% of PanNETs are non-functional (1, 19). The functioning status has been reported as a favorable characteristic of PanNET, as recurrence occurs in this group in ~4% of cases (9). However, although some F-PanNETs including insulinoma are commonly reported to be benign (20), the prognosis of F-PanNETs is still predominately driven by the tumor stage and pathological features, regardless of hormone secretion (1). It follows that F-PanNETs present with a clinical hormone syndrome that favors diagnosis at early stages. Furthermore, it has been observed that F-PanNETs have a lower median proliferative index and are less likely to have vascular or perineural invasion compared to NF-PanNETs (9). Those features, as discussed later in this review, have a relevant impact on prognosis.

Symptoms

The presence of hormone clinical syndrome in F-PanNET favors early diagnosis and thus surgical resection at early stages. However, for patients with NF-PanNETs the presence of symptoms at diagnosis is usually related to tumor mass effect or tumoral infiltration on the surrounding structures and therefore is associated with worse prognosis (21, 22). To date, because of the recent increased incidental diagnosis of small NF-PanNETs, fewer patients present with symptoms at diagnosis (23). Abdominal pain is the most frequent symptom occurring in 32–50% of symptomatic patients, while weight loss and jaundice are reported less frequently, respectively, 11–22% and 3–7% of the cases (22–24). Compared to incidental tumors, symptomatic PanNETs present with larger tumor size, higher grade, more frequent lymphovascular, and perineural invasion and are usually detected at an advanced stage (23, 24). Not surprisingly, the presence of symptoms at diagnosis, in patients undergoing surgery (stage I–III), is associated with reduced disease-specific survival and progression-free survival at any stage (23).

Tumor Grading

Grading of PanNET is based on the proliferation rate of the neoplastic cells, as determined by the mitotic count and/or the Ki67 labeling index. The current 2019 WHO grading system classifies well-differentiated PanNETs into low- (G1), intermediate- (G2), and high-grade (G3) neoplasms (Table 1). Several retrospective studies have validated the prognostic value of PanNET grading, showing that higher grade is associated with an increased risk of recurrence and shorter overall survival, and to date, it is considered the most significant prognostic factor for disease relapse (9, 14, 17, 25, 26). When evaluating the risk of recurrence, G3 PanNETs have a worse prognosis than G1/G2, whereas G2 PanNETs exhibit up to 11-folded risk to recur compared to G1 neoplasms (4, 9). Patients with G3 PanNET need to be strictly surveilled following curative surgery, whereas the outcomes of G1 and G2 neoplasms are more heterogeneous, and their stratification based solely on grade can be inaccurate. G1 and G2 PanNETs represent 95% of all PanNETs undergoing surgical resection (9). Of those, 68–78% are G1 neoplasms. Recurrence is rare in this group and occurs in up to 4% of cases. However, to date, how to discern G1 PanNETs with increased risk of recurring from those that have been definitively cured by surgery is unclear. On the other hand, the category of G2 PanNET is a gray area that includes both indolent and aggressive neoplasms including tumors harboring a Ki67 that widely ranges between 3 and 20% (9). To better stratify patients, several studies have investigated the prognostic role of Ki67, aiming to identify clinically relevant stratification cutoffs. The analysis of large cohorts revealed that in the subgroup of patients with G1 to G2 tumors, the Ki67 cutoff of 5% was the best to stratify prognosis between those two grades (25, 27, 28). In addition, small variations in Ki67 value below 6% cause much larger variations in oncological outcomes, compared to similar variations for higher values of Ki67 (9). Therefore, the actual Ki67 value contributes to predicting prognosis when considered in a continuous, however non-linear, fashion, underscoring the need to develop mathematical tools to interpret Ki67 as a continuous variable.

Tumor Size

PanNET tumor size has been confirmed as an important prognostic feature. Large tumors are associated with an increased risk to recurrence and worse survival (9, 25). PanNETs larger than 4 cm are, in ≥50% of cases, intermediate-/high-grade neoplasms and with nodal metastases at the time of resection (21). Conversely, NF-PanNETs smaller than 2 cm are usually low-grade tumors (84–95%) with no nodal involvement (86–99%) and uncommonly demonstrate clinical aggressiveness (1, 21, 29). Because of their uncertain malignant potential, the European Neuroendocrine Tumor Society (ENETS) suggests that managing NF-PanNETs ≤2 cm with a “wait and watch” strategy and to limit surgery to those who experience tumor growth during the follow-up. However, 7–17% of small PanNETs have malignant potential based on their tumor grade; therefore, an accurate diagnostic workup must be performed before establishing the best management strategy (21, 30, 31). Small PanNETs undergoing surgery should therefore be followed according to tumor grade, stage, and other pathological features.

Lymphovascular and Perineural Invasion

Lymphovascular invasion (LVI) is defined as the presence of tumor cells within a definite endothelial-lined lymphatic or blood vessel in the pancreas surrounding the PanNET, while the presence of tumoral cells along nerves or within the layers of nerve fiber is categorized as perineural invasion (PNI). Lymphatic and vascular invasions are usually associated and reported as a single character on the pathology report. Conversely, PNI is a distinct pathologic entity observable in the absence of LVI. The rate of LVI and PNI in PanNETs rages from 22–36% to 17–39%, respectively (9, 14, 22, 32). Vascular and lymphatic vessels and nerves can potentially be a route of metastatic spread to regional lymph nodes and distant organs and are therefore considered a histologic indicator of aggressive tumor behavior. Indeed, the presence of LVI is associated with an x4-8 and PNI x2-6 risk of recurrence (9, 15, 22). Because PanNET recurrence is rare, multivariable analysis of predictive factors is often challenging. As a result, it remains unclear whether LVI and PNI are independent predictors of recurrence. However, although they are associated with larger tumor size and higher tumor grade, they have been often included as separate variables in several prediction tools, suggesting significant contributions in defining prognosis (9, 15, 33).

Main Pancreatic Duct Involvement

Rarely, PanNET has an infiltrative growth pattern involving the main pancreatic duct (MPD) causing its stenosis or complete obstruction. However, when present it is associated with tumor aggressiveness (34, 35). On imaging, those neoplasms more often arise in the pancreatic head; however, occasionally a clear mass is not visible on imaging and the MPD dilation might be the only suggestive finding (34). Some PanNETs are pathologically characterized by an unusual prominent stromal fibrosis that can involve the MPD, contributing to stenosis and consequent upstream dilation with associated pancreatic atrophy (34). In a series including 101 patients undergoing surgery for PanNET, MPD stenosis has been identified preoperatively, on magnetic resonance cholangiopancreatography images, in 13% of cases and was associated with an increased recurrence rate (50 vs. 7%) (35). These neoplasms are usually larger than 1.5 cm and have frequent nodal involvement (77 vs. 13%) compared to PanNET without MPD involvement, independently of tumor grade (35). Pathologically, strong and diffuse serotonin immunoreactivity has been observed (34).

Lymph-Node Status

Patients undergoing surgery for PanNET have lymph-node metastasis (pN+) in 26–37% of cases (32, 36, 37). While the association of nodal metastasis with overall survival remains controversial, several studies have now demonstrated the correlate of pN+ with recurrence (6, 9, 16, 32, 36–38). Patients with lymph nodal involvement have a ×5 risk of recurrence following curative resection and a reduced 5-year disease-free survival (DFS) from 86–97% to 60–70% compared to patients with no nodal involvement (36, 37). The ENETS/AJCC staging system classifies PanNET with pN+ as N1, regardless of the nodal burden supported by several studies, suggesting that the number of metastatic lymph nodes fails to impact DFS (36, 37, 39). Several preoperative predictors for pN+ have been identified. On preoperative cross-sectional imaging, the finding of enlarged lymph nodes that might appear hypervascular is strongly suggestive of nodal involvement (36). The use of 68Ga-DOTATATE PET/CT for baseline staging can show a pathological uptake in abdominal retroperitoneal nodal sites with higher accuracy than CT scans (18, 37). Although survival benefit of extended lymphadenectomy has not been proved, formal surgical resection (pancreaticoduodenectomy or distal pancreatectomy) with regional lymphadenectomy should be performed in PanNET at increased risk of nodal disease to allow an accurate pathological staging (6, 19, 36). Lymphadenectomy should always be performed for a PanNET size larger than 4 cm or for those who had a preoperative biopsy showing Ki67 >3%, and gastrinoma due to the high likelihood of having pN+ (19, 36, 37). For those patients at risk of pN+, the optimal number of harvested lymph nodes is 11–15 (6). Finally, during atypical resection such as middle pancreatectomy or enucleation performed to resect selected small NF-PanNETs, nodal sampling may be routinely justified to improve disease staging (40).

Margin Status

Oncological curative surgery aims to achieve negative resection margins (R0); however, microscopic residual disease on margins (R1) is described in 6–15% of PanNET resections (9, 15, 41). Whether the R1 status is impacting on survival is still debated, and several studies have reported that this condition is associated with recurrence (9, 14, 32, 41, 42). In a previous study, we have observed that patients with R1 margins experienced recurrence in 37 vs. 10% of those with R0 resection (9). Zhang et al. reported a reduced 10-yr recurrence-free survival from 63 to 47% for R1 resections (41). Dong et al., evaluating the pattern of recurrence on a cohort of 1,020 patients, identified the R1 status as an independent prognostic factor for local recurrence but not liver recurrence (14). However, tumors with R1 resection are more likely to be larger, with nodal metastases, LVI, and PNI; it is currently debated whether the margin status is an independently biological metric (14, 41). Finally, the only study evaluating the impact of re-resection of an initially positive margin to achieve R0 demonstrated no benefit in terms of recurrence-free survival or overall survival (41).

Circulating Biomarkers

Serum Chromogranin A

Chromogranin A (CgA) is a glycoprotein stored in the secretory granules of normal neuroendocrine cells and, by measuring in serum or plasma, can be used as a circulating biomarker for the diagnosis and surveillance of PanNETs. Several studies have suggested that CgA is a reliable diagnostic biomarker for PanNETs with increased CgA values associated with higher tumor grade and stage and liver metastasis and might serve as a prognostic marker for both progression-free and overall survival (43, 44). For these reasons, both ENETS and NCCN guidelines advocate serial CgA evaluation during follow-up following curative surgery, whereas NANETS recommends its assessment only for patients with elevated values preoperatively (12, 13, 45). However, increased serum levels are reported in only a quarter of patients with resectable disease and CgA value at diagnosis is not predictive of recurrence after surgery, calling into question CgA clinical utility in this setting (46, 47). Furthermore, CgA increase during follow-up has shown a low positive predictive value, suffering from almost 50% false-positive rates and therefore lacking sufficient specificity to effectively monitor these patients (47, 48). Indeed, CgA levels can increase in association with many other medical conditions such as renal failure and non-neuroendocrine neoplasms, and in patients taking proton-pump inhibitors (46, 49). Finally, interpreting CgA values can be challenging due to the lack of standardization among available assays and measurements across different laboratories, further limiting its use as biomarker for recurrence prediction.

Peripheral Inflammatory Blood Markers

There is increasing evidence that the systemic inflammatory response plays a role in promoting tumorigenesis and cancer progression for many malignancies (50). The neutrophil–lymphocyte ratio (NLR) is a marker of systemic inflammation which has been reported to predict oncological outcomes in patients with several cancer types (51–54) and can be easily obtained by a routine blood-count analysis. A few retrospective studies have evaluated NLR's role as a biomarker to predict recurrence of PanNET following curative surgery (55, 56). Increased preoperative NLR has been associated with higher Ki67, presence of nodal and liver metastasis, LVI, and PNI (56). Values above 3.4–3.7 at surgery have been found prognostic of recurrence following curative resection; however, NLR values are affected by several other medical conditions as concomitant infection, inflammatory disorders, and use of drugs, including steroids, therefore accurate studies controlling for these factors are required (55, 56). To date, only a small study including 34 patients has prospectively evaluated the prognostic values of NLR for PanNETs undergoing surgery without finding any prognostic relevance (57). Other inflammatory markers were found to be prognostic such as the lymphocyte-to-monocyte ratios and the platelet-to-lymphocyte ratio. However, due to the limited data available, to date, the prognostic significance of these markers needs to be further investigated in larger prospective studies.

Neuroendocrine mRNA Genomic Biomarker (NETest)

Developing molecular biomarkers detectable by blood-based assays has held great promise to finally facilitate real-time management of the disease for PanNET. NETest is a multi-analyte transcript-based biomarker evaluated on blood samples, extensively investigated over the last few years (58). This test is based upon quantitative reverse-transcription PCR measurement of 51 gene-circulating markers, originally identified by comparing upregulated gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) transcriptomes and circulating blood transcripts (mRNA) (58, 59). NETest provides a final score ranging between 0 and 100%; a score >20% is diagnostic of neuroendocrine neoplasms (accuracy 95%, specificity 95–98%, sensitivity 89–94%) (59). Changes in NETest levels have been shown to provide meaningful information on the response to treatment with somatostatin analogs and PRRT (59–61). Two prospective studies have also demonstrated that surgical resection of GEP-NEN and PanNET decreases NETest postoperative blood levels and that patients with residual disease have higher levels compared to those receiving an R0 resection (62, 63). Partelli et al. reported that blood transcript levels return to normal (<20%) by 30th postoperative day in 15/30 of patients (63). Among those with persistently high levels, 3 patients had transcript levels >40%, 2 of those with proven residual disease. The remaining 12 patients exhibited only moderate transcript levels (20–40%) in the absence of radiologically detectable disease. Currently, without data on surveillance, the prognostic significance of NETest in this range of values remains unclear. Another study by Genç et al. demonstrated that a NETest value >20% is not uncommon at follow-up of patients with no recurrence following surgery, whereas a cutoff of 40% has an accuracy of 83% in detecting recurrent disease (48). Although results from these preliminary studies are promising, long-term data from these series and further independent prospective studies are still needed to clarify the role of NETest as a biomarker for both detection of residual disease and monitoring patients for recurrence following surgery.

Prediction Tools

As discussed in this review, there are many clinical and pathological factors associated with recurrence of PanNETs. However, to date, none of them in isolation provides an accurate assessment of recurrence risk for patients undergoing curative surgery of localized disease. The ENETS/AJCC staging system includes tumor size, local disease extent, presence of lymph-node metastases, and distant metastases (TNM system); however, it fails to incorporate tumor-grade assessment, resulting in patients with a different tumor biology included in the same class of risk (9, 39, 64). To overcome this problem and improve prognostication, predictive models and nomograms incorporating multiple variables have been developed, and their characteristics are summarized in Table 2.

TABLE 2

Table 2. Summary of predictive tools.

Several studies have developed scoring systems to group patients sharing similar clinicopathological characteristics into defined classes of risk (i.e., low-, intermediate-, and high-risk) (15, 22, 66, 67). In a large study by Zaidi et al. including 1,006 patients, the authors developed and validated a prediction model that assigns points according to the presence of symptoms (1 point), tumor diameter (≥2 cm: 2 points), Ki67 (<3, 3–20, and >20%, respectively, 0, 1, and 6 points), and presence of lymph nodal metastasis (1 point) (22). Based on the final score obtained by summating the points in each category, patients are classified as low-risk (0–2 points), intermediate-risk (3–5 points), and high-risk (6–10 points) of recurrence. Patients in the low-, intermediate-, and high-risk groups had 5, 22, and 56% recurrence rate (P < 0.0019). The authors provided a surveillance schedule based on the risk score suggesting a follow-up every 3 months for patients at high risk and every 6 and 12 months respectively for those with an intermediate and low risk to recur. Although this approach is pragmatic and can easily be applied in clinical practice, accuracy remains limited as each category comprises a heterogeneous group of patients. For example, applying this score, patients with G1 or G2 PanNET, >2 cm with pN+, are both classified into the same intermediate risk despite the potential for significantly divergent prognosis. Another scoring system to predict recurrence has been developed by Genc et al. utilizing a cohort of 211 patients. Patients were scored according to tumor grading (G1 and G2, 0 point and 40 points), presence of positive lymph nodes (24 points), and presence of PNI (24 points). While this model potentially allows an estimation of a patient's individual probability of recurrence, only categorical variables were included, limiting the range of possible scores to six categories and with no clear improvements compared to the conventional staging systems (15).

An alternative approach to predict recurrence is represented by nomograms. A nomogram is a graphical representation of mathematical formulas that estimate the individualized risk of a clinical event. This method has recently emerged to be particularly accurate for prognosis prediction in oncology. While in traditional staging systems and risk grouping models continuous variables are converted to categorical, a nomogram allows the incorporation of continuous variable, therefore adding important information provided by the actual value to the model. Compared to risk groups, nomograms are more complex models and their use in clinical practice can be more complicated. However, this increased complexity results in a better predictive accuracy and can be overcome by using electronic versions of nomograms that facilitate the data input, score computing, and risk assessment.

Several groups have proposed this approach, and two different nomograms have been developed to predict PanNET recurrence (9, 22) (Table 2). The US Neuroendocrine Tumor Study Group developed a nomogram on a large cohort of gastroenteropancreatic tumors to predict recurrence following surgery (65). This model includes four variables: Ki67 value, lymph nodal status, tumor size, and presence of invasion of adjacent organs. The model performance was evaluated with a c-index, with 0.71 achieved in the test cohort. This index expresses the ability of the prediction model to distinguish between patients who had recurrence from those who did not. A value of 0.5 indicates that the model is no better than chance, a value above 0.70 identifies a good model, and a value above 0.80 indicates a strong model, whereas a c-index of 1.0 indicates a perfect prediction model (68, 69). Although it was developed on a large cohort of patients who had good performance, this model was not specific for PanNETs, representing a significant limitation as PanNETs have demonstrated different patterns and timescales of recurrence compared with neuroendocrine tumors from other gastrointestinal sites (70). A second nomogram has been proposed by our group, in a collaborative study on a large multi-institutional cohort of surgically resected G1/G2 PanNETs (9). The model has been developed on a cohort of 632 patients treated at two institutions and then externally validated on a cohort of 328 patients undergoing surgery in three different hospitals. The nomogram included four variables: Ki67 value, tumor diameter, number of positive lymph nodes, and presence of LVI and/or PNI. The model obtained promising results as the c-index achieved a value of 0.84 in the validation cohort, which was higher than those achieved by the ENETS/AJCC staging system and WHO grading system (c-index 0.76 for both) and any other prognostic model currently published and validated. Although these results are intriguing, the utility of such tools has not been yet translated into clinical practice. At this time, none of these prognostic models have been prospectively validated nor employed to select patients for clinical trials or to improve surveillance strategies. In addition, none of them have been developed to compute the risk of recurrence after the first 5 years of surgical follow-up.

Molecular Markers

Over recent years, thanks to the advancements in high-throughput sequencing techniques, the genomic and transcriptomic landscape of sporadic PanNETs has been defined, leading to the identification of recurrent molecular alterations. However, the biological role that each molecular alteration plays in promoting PanNET initiation and progression still requires elucidation. Retrospective genetic studies have shown that some recurrent genetic mutations are associated with an increased risk of metastatic spread, suggesting that their identification might serve as prognostic biomarkers to improve the clinical decision-making process. However, the majority of these findings have not been yet validated in a prospective clinical setting or translated into routine clinical practice.

Germline Alterations

The initial knowledge of molecular alterations in PanNET was derived from patients with hereditary tumor predisposition syndromes. Familial syndromes are usually caused by a deleterious germline mutation that increases the overall risk of developing a neuroendocrine neoplasm throughout the entire pancreas and in other organs harboring neuroendocrine cells. Key syndromes include multiple endocrine neoplasia type 1 (MEN1), von Hippel–Lindau disease (VHL), neurofibromatosis type 1 (NF1), and tuberous sclerosis complex (TSC), which are characterized by germline mutations in the tumor-suppressor genes MEN1, VHL, NF1, and TSC1 or TSC2, respectively.

The MEN1 syndrome is an autosomal-dominant syndrome with a prevalence of 2–3 per 100,000 that affects the pancreas in 30–80% of MEN1 patients, the parathyroid glands, and less frequently the duodenum and the pituitary gland (71). Compared with sporadic PanNET, pancreatic tumors arising in MEN1 patients are characterized by early-onset and multiple pancreatic microadenomas, which can ultimately progress to larger tumors and are often the first neoplastic cause for MEN1 patients' mortality (72, 73). Patients with VHL syndrome present with PanNETs in 10–17% of cases, although other pancreatic neoplasms can be associated with this syndrome, including pancreatic serous cystadenomas and mixed serous cystadenoma-PanNETs (uncommon outside the VHL syndrome) (74). PanNETs are usually well-differentiated, and only occasionally locally advanced or metastatic disease has been reported (75). Pancreatic involvement in NF1 and TSC is less common. In patients with NF1 syndrome, pancreatic tumors are described in 10% of cases; however, these neoplasms are often somatostatinomas that often arise in the duodenum rather than in the pancreas and are characterized by distinct genomic alterations (76, 77). Finally, TSC patients present with pancreatic involvement in only 1%, with both functional and non-functional PanNETs reported (78). Recently, other germline mutations have been described as being associated with PanNET outside these well-known familiar syndromes. Whole-genome sequencing analysis of a large cohort of 98 cases of apparently sporadic PanNETs have identified a higher than expected rate of germline alterations (79). These included germline mutations in MUTYH, whose biallelic inactivation was associated with a novel signature in 5% cases and BRCA2 in 1 case (associated with the respective signature). Germline mutations coupled with LOH were also reported in CHEK2, MEN1, VHL, and CDKN1B (MEN4 syndrome), respectively, in 4, 6, 1, and 1 cases.

Somatic Mutation

MEN 1

MEN1 mutation is detected in 25–44% of resected tumors while the MEN 1 locus, on chromosome 11q13, is also frequently lost by chromosomal alterations in 70% of the cases (79–81). The protein-encoded menin is involved in several cellular pathways, including chromatin remodeling, DNA replication, and histone methylation, and MEN1 mutation has been also correlated with increased telomere length suggesting a role in chromosome maintenance (79). However, MEN1 mutations are independent from those in DAXX and ATRX, which are associated with increased telomere length, indicating that they function in different pathways. Despite the high prevalence of MEN1 mutations, inconsistent results have emerged regarding their potential clinical role. Initial observations on metastatic PanNETs suggested that MEN1 mutations, in combination with DAXX or ATRX mutations, are associated with prolonged survival (80, 82). However, clinical series that specifically investigated the clinical significance of MEN1 loss of function in primary resected PanNET failed to demonstrate a correlation with oncological outcomes (83, 84).

mTOR

The mTOR pathway plays a key role in several neoplasms, including PanNETs. Mutations in genes encoding proteins functioning in the mTOR pathway are present in almost 12–15% of PanNETs and include PTEN, TSC1, TSC2, and PIK3CA and the recently described DEPDC5 (80). However, besides somatic mutations, other biological mechanisms are involved in the upregulation of the mTOR pathway, as demonstrated by the reduced expression of tumor suppressors functioning in the mTOR axis and the clinical efficacy of agents targeting the pathway, such as everolimus (85, 86). Also, PanNETs harboring mutations in the mTOR pathway have a higher Ki67 and a poor prognosis, suggesting that mutations in these genes might serve as prognostic markers, in particular in the heterogeneous category of G2 tumors (87).

DAXX/ATRX

Inactivating somatic mutations in either DAXX (25%) or ATRX (18%) genes are present in almost half of PanNETs (80). Mutations in DAXX or ATRX are strongly associated with increased telomere length and are mutually exclusive, confirming that the protein encoded works within the same pathway (88, 89). An increase in telomere length characterizes the alternative lengthening of telomeres (ALT) phenotype, a telomerase-independent mechanism of telomere maintenance, important for the survival of telomerase-negative cancer cells and that has been associated with specific patterns of chromosome alterations (79, 82). The ALT phenotype can be detected on biopsy or resected specimens through telomere-specific FISH and correlate almost perfectly with the DAXX/ATRX status (mutation or protein loss at IHC analysis), whereas only in very rare cases ALT + PanNETs lack mutations in DAXX and ATRX (88, 90). Initial reports suggested that the ALT phenotype was associated with longer survival in patients with metastatic PanNETs, whereas subsequent studies that specifically investigated ALT prevalence in a large cohort of primary resected PanNETs have shown that ALT, in localized disease, is strongly associated with larger size and higher Ki67 and with metastatic progression (89, 91, 92).

Gene Expression Signatures

Recent RNA-seq analysis has identified PanNET gene expression signatures that represent distinct endocrine cell lineages and that can predict outcomes following resection (93, 94). The different signatures present similarities with genes that are specifically expressed in islet α- and β-cells and can be specified by the enhanced expression of the transcription factor ARX and PDX1, respectively (94–96). PanNETs with “alpha cell-like” expression form a distinct subgroup that often contain mutation in MEN1, DAXX, or ATRX and an ALT positive phenotype. These tumors are characterized by ARX positivity through IHC and by worse prognosis following resection, especially when associated with ALT (94, 95). PanNETs exhibiting beta-cell lineage-specific gene stain positive for PDX1 infrequently exhibit ALT and rarely recur following resection (94, 95). IHC for ARX and PDX1 are promising factors to assess prognosis; however, further validation on larger cohorts is warranted before they can be considered for clinical application.

Conclusion

Clinical and pathological factors determining PanNET recurrence after surgery are numerous (Table 3). None of them alone allow an accurate estimation of the risk of recurrence, and it remains unclear which patients should be surveilled closely, with which schedule, and for how long after curative pancreatic resection. Currently, nomograms represent the most accurate and discriminating tools for predicting recurrence in patients with PanNET, enabling the integration of multiple variables. These tools can be used by physicians to provide treatment and follow-up recommendations; however, prospective validation of such models is still required. Moreover, as yet none of these models is capable to of predicting long-term recurrence-free survival (up to 10 year). Therefore, although they can provide help in planning an appropriate follow-up, none is currently capable of selecting of patients for which the postsurgical surveillance can be discontinued. In addition, while many genomic alterations have shown to carry a prognostic significance in retrospective studies, these have not been integrated with clinical and pathological variables in a prospective setting. For future strategies, current clinical prediction tools should be integrated with the results of genomic and transcriptomic sequencing techniques and ALT evaluation. Novel biomarkers, larger data sets, longer follow-up, and more sophisticated modeling procedures will ultimately improve prognostic accuracy and enhance management of this heterogeneous group of neoplasms.

TABLE 3

Table 3. Summary of most relevant clinical, pathological, and molecular worrisome features for postsurgical recurrence.

Author Contributions

APu and APe wrote and edited the manuscript, created the figure, and created the tables. NJ and DC edited and critically revised the manuscript. All authors read and approved the final manuscript for publication.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Klimstra DS, Kloppell G, La Rosa S RG. Classification of neuroendocrine neoplasms of the digestive system. In: Board WC, editor. WHO Classification of Tumours of the Digestive System Tumours. 5th ed. Lyon: International Agency for Research on Cancer (2019). p. 16.

Google Scholar

2. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united states. JAMA Oncol. (2017) 26:2124–30. doi: 10.1001/jamaoncol.2017.0589

CrossRef Full Text

3. Pulvirenti A, Marchegiani G, Pea A, Allegrini V, Esposito A, Casetti L, et al. Clinical Implications of the 2016. International study group on pancreatic surgery definition and grading of postoperative pancreatic fistula on 775 consecutive pancreatic resections. Ann Surg. (2018) 268:1069–75. doi: 10.1097/SLA.0000000000002362

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Tang LH, Untch BR, Reidy DL, O'Reilly E, Dhall D, Jih L, et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin Cancer Res. (2016) 22:1011–7. doi: 10.1158/1078-0432.CCR-15-0548

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Haugvik SP, Janson ET, Österlund P, Langer SW, Falk RS, Labori KJ, et al. Surgical treatment as a principle for patients with high-grade pancreatic neuroendocrine carcinoma: a nordic multicenter comparative study. Ann Surg Oncol. (2016) 23:1721–8. doi: 10.1245/s10434-015-5013-2

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, et al. The North American neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. (2020) 49:1–33. doi: 10.1097/MPA.0000000000001454

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Öberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2012) 23:mds295. doi: 10.1093/annonc/mds295

PubMed Abstract | CrossRef Full Text

8. Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. (2016) 103:186–94. doi: 10.1159/000443172

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Pulvirenti A, Javed AA, Landoni L, Jamieson NB, Chou JF, Miotto M, et al. Multi-institutional development and external validation of a nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors. Ann Surg. (2019) doi: 10.1097/SLA.0000000000003579. [Epub ahead of print].

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, et al. The north American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas. (2017) 46:707–14. doi: 10.1097/MPA.0000000000000850

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, et al. Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors. JAMA Oncol. (2018) 4:1597–604. doi: 10.1001/jamaoncol.2018.2428

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Knigge U, Capdevila J, Bartsch DK, Baudin E, Falkerby J, Kianmanesh R, et al. ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms: follow-up and documentation. Neuroendocrinology. (2017) 105:310–9. doi: 10.1159/000458155

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. (2013) 42:557–77. doi: 10.1097/MPA.0b013e31828e34a4

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Dong D-H, Zhang X-F, Lopez-Aguiar AG, Poultsides G, Makris E, Rocha F, et al. Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence. HPB. (2020) 22:215–23. doi: 10.1016/j.hpb.2019.05.020

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Genç CG, Jilesen AP, Partelli S, Falconi M, Muffatti F, van Kemenade FJ, et al. A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors. Ann Surg. (2018) 267:1148–54. doi: 10.1097/SLA.0000000000002123

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Boninsegna L, Panzuto F, Partelli S, Capelli P, Fave GD, Bettini R, et al. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer. (2012) 48:1608–15. doi: 10.1016/j.ejca.2011.10.030

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Marchegiani G, Landoni L, Andrianello S, Masini G, Cingarlini S, D'Onofrio M, et al. Patterns of recurrence after resection for pancreatic neuroendocrine tumors: who, when, and where? Neuroendocrinology. (2019) 108:161–71. doi: 10.1159/000495774

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, et al. Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. (2016) 34:588–97. doi: 10.1200/JCO.2015.64.0987

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. (2016) 103:153–71. doi: 10.1159/000443171

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma—incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. (1991) 66:711–9. doi: 10.1016/S0025-6196(12)62083-7

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Bettini R, Partelli S, Boninsegna L, Capelli P, Crippa S, Pederzoli P, et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery. (2011) 150:75–82. doi: 10.1016/j.surg.2011.02.022

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Zaidi MY, Lopez-Aguiar AG, Switchenko JM, Lipscomb J, Andreasi V, Partelli S, et al. A novel validated recurrence risk score to guide a pragmatic surveillance strategy after resection of pancreatic neuroendocrine tumors: an international study of 1006. Patients Ann Surg. (2019) 270:422–33. doi: 10.1097/SLA.0000000000003461

CrossRef Full Text | Google Scholar

23. Crippa S, Partelli S, Zamboni G, Scarpa A, Tamburrino D, Bassi C, et al. Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors. Surgery. (2014) 155:145–53. doi: 10.1016/j.surg.2013.08.002

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Baptiste GG, Postlewait LM, Ethun CG, Le N, McInnis MR, Russell MC, et al. Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: a single institution experience over 15 years. J Surg Oncol. (2016) 114:163–9. doi: 10.1002/jso.24279

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. (2010) 23:824–33. doi: 10.1038/modpathol.2010.58

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Kim MJ, Choi DW, Choi SH, Heo JS, Park HJ, Choi KK, et al. Surgical strategies for non-functioning pancreatic neuroendocrine tumours. Br J Surg. (2012) 99:1562–8. doi: 10.1002/bjs.8892

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW, et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst. (2012) 104:764–77. doi: 10.1093/jnci/djs208

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Genç CG, Falconi M, Partelli S, Muffatti F, van Eeden S, Doglioni C, et al. Recurrence of pancreatic neuroendocrine tumors and survival predicted by Ki67. Ann Surg Oncol. (2018) 25:2467–74. doi: 10.1245/s10434-018-6518-2

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Sadot E, Reidy-Lagunes DL, Tang LH, Do RK, Gonen M, D'Angelica MI, et al. Observation versus resection for small asymptomatic pancreatic neuroendocrine tumors: a matched case-control study. Ann Surg Oncol. (2016) 23:1361–70. doi: 10.1245/s10434-015-4986-1

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Haynes AB, Deshpande V, Ingkakul T, Vagefi PA, Szymonifka J, Thayer SP, et al. Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors. Arch Surg. (2011) 146:534–8. doi: 10.1001/archsurg.2011.102

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Cherenfant J, Stocker SJ, Gage MK, Du H, Thurow TA, Odeleye M, et al. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery. (2013) 154:785–91. doi: 10.1016/j.surg.2013.07.004

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Hashim YM, Trinkaus KM, Linehan DC, Strasberg SS, Fields RC, Cao D, et al. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg. (2014) 259:197–203. doi: 10.1097/SLA.0000000000000348

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Nanno Y, Toyama H, Otani K, Asari S, Goto T, Terai S, et al. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence. Pancreatology. (2016) 16:882–7. doi: 10.1016/j.pan.2016.06.008

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Shi C, Siegelman SS, Kawamoto S, Wolfgang CL, Schulick RD, Maitra A, et al. Pancreatic duct stenosis secondary to small endocrine neoplasms: a manifestation of serotonin production? Radiology. (2010) 257:107–14. doi: 10.1148/radiol.10100046

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Nanno Y, Matsumoto I, Zen Y, Otani K, Uemura J, Toyama H, et al. Pancreatic duct involvement in well-differentiated neuroendocrine tumors is an independent poor prognostic factor. Ann Surg Oncol. (2017) 24:1127–33. doi: 10.1245/s10434-016-5663-8

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Partelli S, Gaujoux S, Boninsegna L, Cherif R, Crippa S, Couvelard A, et al. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs). JAMA Surg. (2013) 148:932–9. doi: 10.1001/jamasurg.2013.3376

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Lopez-Aguiar AG, Zaidi MY, Beal EW, Dillhoff M, Cannon JGD, Poultsides GA, et al. Defining the role of lymphadenectomy for pancreatic neuroendocrine tumors: an eight-institution study of 695 patients from the US neuroendocrine tumor study group. Ann Surg Oncol. (2019) 26:2517–24. doi: 10.1245/s10434-019-07367-y

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Harimoto N, Hoshino K, Muranushi R, Hagiwara K, Yamanaka T, Ishii N, et al. Significance of lymph node metastasis in resectable well-differentiated pancreatic neuroendocrine tumor. Pancreas. (2019) 48:943–7. doi: 10.1097/MPA.0000000000001355

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Bergsland EK, Woltering EA, Rindi G, O'Dorisio TM, Schilsky RL, et al. Neuroendocrine tumors of the pancreas. In: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al., editors. AJCC Cancer Staging Man. 8th ed. Cham: Springer International Publishing (2017).

40. Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours. Neuroendocrinology. (2017) 105:255–65. doi: 10.1159/000464292

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Zhang XF, Wu Z, Cloyd J, Lopez-Aguiar AG, Poultsides G, Makris E, et al. Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: results from the US neuroendocrine tumor study group. Surgery. (2019) 165:548–56. doi: 10.1016/j.surg.2018.08.015

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors analysis of 3851 patients. Ann Surg. (2008) 247:490–500. doi: 10.1097/SLA.0b013e31815b9cae

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Massironi S, Rossi RE, Casazza G, Conte D, Ciafardini C, Galeazzi M, et al. Chromogranin a in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Neuroendocrinology. (2014) 100:240–9. doi: 10.1159/000369818

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Hijioka M, Ito T, Igarashi H, Fujimori N, Lee L, Nakamura T, et al. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors. Cancer Sci. (2014) 105:1464–71. doi: 10.1111/cas.12533

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Chan DL, Moody L, Segelov E, Metz DC, Strosberg JR, Pavlakis N, et al. Follow-up for resected gastroenteropancreatic neuroendocrine tumours: a practice survey of the commonwealth neuroendocrine tumour collaboration (CommNETS) and the North American neuroendocrine tumor society (NANETS). Neuroendocrinology. (2018) 107:32–41. doi: 10.1159/000488394

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Pulvirenti A, Rao D, Mcintyre CA, Gonen M, Tang LH, Klimstra DS, et al. Limited role of chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. HPB. (2019) 21:612–8. doi: 10.1016/j.hpb.2018.09.016

PubMed Abstract | CrossRef Full Text | Google Scholar

47. Jilesen APJ, Busch ORC, Van Gulik TM, Gouma DJ, Nieveen Van Dijkum EJM. Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors - diagnostic accuracy: NF-pNET and low tumor burden. Dig Surg. (2014) 31:407–14. doi: 10.1159/000370007

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Genç CG, Jilesen APJ, Nieveen van Dijkum EJM, Klümpen HJ, van Eijck CHJ, Drozdov I, et al. Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors. J Surg Oncol. (2018) 118:37–48. doi: 10.1002/jso.25129

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Kidd M, Bodei L, Modlin IM. Chromogranin A: any relevance in neuroendocrine tumors? Curr Opin Endocrinol Diabetes Obes. (2016) 23:28–37. doi: 10.1097/MED.0000000000000215

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. (2010) 140:883–99. doi: 10.1016/j.cell.2010.01.025

PubMed Abstract | CrossRef Full Text | Google Scholar

51. McIntyre CA, Pulvirenti A, Lawrence SA, Seier K, Gonen M, Balachandran VP, et al. Neutrophil-to-lymphocyte ratio as a predictor of invasive carcinoma in patients with intraductal papillary mucinous neoplasms of the pancreas. Pancreas. (2019) 48:832–6. doi: 10.1097/MPA.0000000000001342

PubMed Abstract | CrossRef Full Text | Google Scholar

52. Jeong JH, Lim SM, Yun JY, Rhee GW, Lim JY, Cho JY, et al. Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer. Oncology. (2012) 83:292–9. doi: 10.1159/000342376

PubMed Abstract | CrossRef Full Text | Google Scholar

53. Mano Y, Shirabe K, Yamashita YI, Harimoto N, Tsujita E, Takeishi K, et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg. (2013) 285:301–5. doi: 10.1097/SLA.0b013e318297ad6b

CrossRef Full Text | Google Scholar

54. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol. (2009) 16:614–22. doi: 10.1245/s10434-008-0267-6

PubMed Abstract | CrossRef Full Text | Google Scholar

55. Panni RZ, Lopez-Aguiar AG, Liu J, Poultsides GA, Rocha FG, Hawkins WG, et al. Association of preoperative monocyte-to-lymphocyte and neutrophil-to-lymphocyte ratio with recurrence-free and overall survival after resection of pancreatic neuroendocrine tumors (US-NETSG). J Surg Oncol. (2019) 120:632–8. doi: 10.1002/jso.25629

PubMed Abstract | CrossRef Full Text | Google Scholar

56. Harimoto N, Hoshino K, Muranushi R, Hagiwara K, Yamanaka T, Ishii N, et al. Prognostic significance of neutrophil–lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages. Pancreatology. (2019) 19:897–902. doi: 10.1016/j.pan.2019.08.003

PubMed Abstract | CrossRef Full Text | Google Scholar

57. Gaitanidis A, Patel D, Nilubol N, Tirosh A, Sadowski S, Kebebew E. Markers of systemic inflammatory response are prognostic factors in patients with pancreatic neuroendocrine tumors (PNETs): a prospective analysis. Ann Surg Oncol. (2018) 25:122–30. doi: 10.1245/s10434-017-6241-4

PubMed Abstract | CrossRef Full Text | Google Scholar

58. Kidd M, Drozdov I, Modlin I. Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocr Relat Cancer. (2015) 22:561–75. doi: 10.1530/ERC-15-0092

PubMed Abstract | CrossRef Full Text | Google Scholar

59. Öberg K, Califano A, Strosberg JR, Ma S, Pape U, Bodei L, et al. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann Oncol. (2020) 31:202–12. doi: 10.1016/j.annonc.2019.11.003

PubMed Abstract | CrossRef Full Text | Google Scholar

60. Bodei L, Kidd M, Modlin IM, Severi S, Drozdov I, Nicolini S, et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. (2016) 43:839–51. doi: 10.1007/s00259-015-3250-z

PubMed Abstract | CrossRef Full Text | Google Scholar

61. Cwikła JB, Bodei L, Kolasinska-Cwikła A, Sankowski A, Modlin IM, Kidd M. Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy. J Clin Endocrinol Metab. (2015) 100:E1437–45. doi: 10.1210/jc.2015-2792

PubMed Abstract | CrossRef Full Text | Google Scholar

62. Modlin IM, Frilling A, Salem RR, Alaimo D, Drymousis P, Wasan HS, et al. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. Surgery. (2016) 159:336–47. doi: 10.1016/j.surg.2015.06.056

PubMed Abstract | CrossRef Full Text | Google Scholar

63. Partelli S, Andreasi V, Muffatti F, Schiavo Lena M, Falconi M. Circulating neuroendocrine gene transcripts (NETest): a postoperative strategy for early identification of the efficacy of radical surgery for pancreatic neuroendocrine tumors. Ann Surg Oncol. (2020) doi: 10.1245/s10434-020-08425-6. [Epub ahead of print].

PubMed Abstract | CrossRef Full Text | Google Scholar

64. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, De Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. (2006) 449:395–401. doi: 10.1007/s00428-006-0250-1

PubMed Abstract | CrossRef Full Text | Google Scholar

65. Merath K, Bagante F, Beal EW, Lopez-Aguiar AG, Poultsides G, Makris E, et al. Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: an analysis of the U.S. neuroendocrine tumor study group. J Surg Oncol. (2018) 117:868–78. doi: 10.1002/jso.24985

PubMed Abstract | CrossRef Full Text | Google Scholar

66. Sho S, Court CM, Winograd P, Toste PA, Pisegna JR, Lewis M, et al. A prognostic scoring system for the prediction of metastatic recurrence following curative resection of pancreatic neuroendocrine tumors. J Gastrointest Surg. (2019) 23:1392–400. doi: 10.1007/s11605-018-4011-7

PubMed Abstract | CrossRef Full Text | Google Scholar

67. Zou S, Jiang Y, Wang W, Zhan Q, Deng X, Shen B. Novel scoring system for recurrence risk classification of surgically resected G1/2 pancreatic neuroendocrine tumors - retrospective cohort study. Int J Surg. (2020) 74:86–91. doi: 10.1016/j.ijsu.2019.12.034

PubMed Abstract | CrossRef Full Text | Google Scholar

68. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. (2015) 16:e173–80. doi: 10.1016/S1470-2045(14)71116-7

PubMed Abstract | CrossRef Full Text | Google Scholar

69. Gönen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. (2005) 92:965–70. doi: 10.1093/biomet/92.4.965

CrossRef Full Text | Google Scholar

70. Singh S, Chan DL, Moody L, Liu N, Fischer HD, Austin PC, et al. Recurrence in resected gastroenteropancreatic neuroendocrine tumors. JAMA Oncol. (2018) 4:583–5. doi: 10.1001/jamaoncol.2018.0024

CrossRef Full Text | Google Scholar

71. Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med. (1998) 129:484–94. doi: 10.7326/0003-4819-129-6-199809150-00011

PubMed Abstract | CrossRef Full Text | Google Scholar

72. Pannett AAJ, Thakker RV. Multiple endocrine neoplasia type 1. Endocr Relat Cancer. (1999) 6:449–73. doi: 10.1677/erc.0.0060449

PubMed Abstract | CrossRef Full Text | Google Scholar

73. Triponez F, Dosseh D, Goudet P, Cougard P, Bauters C, Murat A, et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg. (2006) 243:265–72. doi: 10.1097/01.sla.0000197715.96762.68

PubMed Abstract | CrossRef Full Text | Google Scholar

74. Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM, et al. Pancreatic involvement in von Hippel-Lindau disease. The groupe francophone d'etude de la maladie de von hippel-lindau. Gastroenterology. (2000) 119:1087–95. doi: 10.1053/gast.2000.18143

CrossRef Full Text | Google Scholar

75. Corcos O, Couvelard A, Giraud S, Vullierme M-P, Dermot O'Toole, Rebours V, et al. Endocrine pancreatic tumors in von hippel-lindau disease. Pancreas. (2008) 37:85–93. doi: 10.1097/MPA.0b013e31815f394a

PubMed Abstract | CrossRef Full Text | Google Scholar

76. Relles D, Baek J, Witkiewicz A, Yeo CJ. Periampullary and duodenal neoplasms in neurofibromatosis type 1: two cases and an updated 20-year review of the literature yielding 76 cases. J Gastrointest Surg. (2010) 14:1052–61. doi: 10.1007/s11605-009-1123-0

PubMed Abstract | CrossRef Full Text | Google Scholar

77. Noë M, Pea A, Luchini C, Felsenstein M, Barbi S, Bhaijee F, et al. Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. Mod Pathol. (2018) 31:1532–8. doi: 10.1038/s41379-018-0082-y

PubMed Abstract | CrossRef Full Text | Google Scholar

78. Ilgren EB, Westmoreland D. Tuberous sclerosis: unusual associations in four cases. J Clin Pathol. (1984) 37:272–8. doi: 10.1136/jcp.37.3.272

PubMed Abstract | CrossRef Full Text | Google Scholar

79. Scarpa A, Chang DK, Nones K, Corbo V, Patch A-M, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. (2017) 543:65–71. doi: 10.1038/nature21063

PubMed Abstract | CrossRef Full Text | Google Scholar

80. Jiao Y, Shi C, Edil BH, Wilde RF De, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. (2011) 331:1199–203. doi: 10.1126/science.1200609

PubMed Abstract | CrossRef Full Text | Google Scholar

81. Hong X, Qiao S, Li F, Wang W, Jiang R, Wu H, et al. Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system. Gut. (2020) 69:877–87. doi: 10.1136/gutjnl-2018-317233

PubMed Abstract | CrossRef Full Text | Google Scholar

82. Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, et al. Loss of DAXX and ATRX are associated with chromosome. Gastroenterology. (2014) 146:453–60.e5. doi: 10.1053/j.gastro.2013.10.020

PubMed Abstract | CrossRef Full Text | Google Scholar

83. Corbo V, Dalai I, Scardoni M, Barbi S, Beghelli S, Bersani S, et al. MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer. (2010) 17:771–83. doi: 10.1677/ERC-10-0028

PubMed Abstract | CrossRef Full Text | Google Scholar

84. Ohki R, Saito K, Chen Y, Kawase T, Hiraoka N, Saigawa R, et al. PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors. Proc Natl Acad Sci USA. (2014) 111:E2404–13. doi: 10.1073/pnas.1319962111

PubMed Abstract | CrossRef Full Text | Google Scholar

85. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. (2010) 28:245–55. doi: 10.1200/JCO.2008.21.5988

PubMed Abstract | CrossRef Full Text | Google Scholar

86. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St. Peter J, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. (2011) 96:3741–9. doi: 10.1210/jc.2011-0666

PubMed Abstract | CrossRef Full Text | Google Scholar

87. Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA. (2011) 108:21188–93. doi: 10.1073/pnas.1118046108

PubMed Abstract | CrossRef Full Text | Google Scholar

88. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science. (2011) 333:425. doi: 10.1126/science.1207313

PubMed Abstract | CrossRef Full Text | Google Scholar

89. Pea A, Yu J, Marchionni L, Noe M, Luchini C, Pulvirenti A, et al. Genetic analysis of small well-differentiated pancreatic neuroendocrine tumors identifies subgroups with differing risks of liver metastases. Ann Surg. (2020) 271:566–73. doi: 10.1097/SLA.0000000000003022

PubMed Abstract | CrossRef Full Text | Google Scholar

90. VandenBussche CJ, Allison DB, Graham MK, Charu V, Lennon AM, Wolfgang CL, et al. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. Cancer Cytopathol. (2017) 125:544–51. doi: 10.1002/cncy.21857

PubMed Abstract | CrossRef Full Text | Google Scholar

91. de Wilde RF, Heaphy CM, Maitra A, Meeker AK, Edil BH, Wolfgang CL, et al. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. Mod Pathol. (2012) 25:1033–9. doi: 10.1038/modpathol.2012.53

PubMed Abstract | CrossRef Full Text | Google Scholar

92. Singhi AD, Liu TC, Roncaioli JL, Cao D, Zeh HJ, Zureikat AH, et al. Alternative lengthening of telomeres and loss of DAXX/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors. Clin Cancer Res. (2017) 23:600–9. doi: 10.1158/1078-0432.CCR-16-1113

PubMed Abstract | CrossRef Full Text | Google Scholar

93. Sadanandam A, Wullschleger S, Lyssiotis CA, Grotzinger C, Barbi S, Bersani S, et al. A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics. Cancer Discov. (2015) 5:1296–313. doi: 10.1158/2159-8290.CD-15-0068

PubMed Abstract | CrossRef Full Text | Google Scholar

94. Chan CS, Laddha S V, Lewis PW, Koletsky MS, Robzyk K, Da Silva E, et al. ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun. (2018) 9:4158. doi: 10.1101/195214

PubMed Abstract | CrossRef Full Text | Google Scholar

95. Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, et al. Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med. (2019) 25:1260–5. doi: 10.1038/s41591-019-0493-4

CrossRef Full Text | Google Scholar

96. Bramswig NC, Everett LJ, Schug J, Dorrell C, Liu C, Luo Y, et al. Epigenomic plasticity enables human pancreatic α to β cell reprogramming. J Clin Invest. (2013) 123:1275–84. doi: 10.1172/JCI66514

PubMed Abstract | CrossRef Full Text | Google Scholar